Journal
BIOCHEMISTRY
Volume 49, Issue 47, Pages 10039-10041Publisher
AMER CHEMICAL SOC
DOI: 10.1021/bi1016233
Keywords
-
Categories
Funding
- Alzheimer's Drug Discovery Foundation (ADDF)
- American Health Assistant Foundation (AHAF)
- Mitchell Center for Neurodegenerative Diseases
Ask authors/readers for more resources
Tau aggregation is a pathological hallmark of Alzheimer's disease, Parkinson's disease, and many other neurodegenerative disorders known as tauopathies. Tau aggregates take on many forms, and their formation is a multistage process with intermediate stages. Recently, tau oligomers have emerged as the pathogenic species in tauopathies and a possible mediator of amyloid-beta toxicity in Alzheimer's disease. Here, we use a novel, physiologically relevant method (oligomer cross-seeding) to prepare homogeneous populations of tau oligomers and characterize these oligomers in vitro. We show that both A beta and a-synuclein oligomers induce tau aggregation and the formation of beta-sheet-rich neurotoxic tau oligomers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available